Aastrom Biosciences, Inc., a clinical-stage biotechnology company, focuses on the development of cell therapies for use in the treatment of severe chronic ischemic cardiovascular diseases. The company is developing a manufacturing technology platform, the Aastrom Replicell System, which enables the expansion of a various cell types, including the production of multicellular therapies expanded from an adult patients own bone marrow that can be delivered directly to damaged tissues. Its lead product candidate include ixmyelocel-T, to treat patients with severe chronic ischemic cardiovascular diseases, such as advanced heart failure due to dilated cardiomyopathy, the third leading cause of heart failure, and critical limb ischemia. The company was founded in 1989 and is headquartered in Ann Arbor, Michigan.
July 29, 2015
Vericel (VCEL) Q2 financial results will be released on 8/12 at 8 a.m. ET
July 28, 2015
RegMed’s close: what a difference a day makes; everything is a tradeoff
July 28, 2015
Higher open expected; RegMed migration should end as opportunity to buy-back value abounds
July 27, 2015
RegMed’s close: the sector’s fireworks went off on the hour – keep checking the shopping list for the impending reverse
July 27, 2015
Lower open expected; RegMed, after an ugly week - a ticket to BUY?
July 26, 2015
RegMed weekend wrap-up: why should we care what happened last week? It’s a set-up for next week!
July 20, 2015
RegMed’s close: a downer and complacent sector
July 18, 2015
RegMed weekend wrap-up: a ladder is needed to climb up and down the tape
July 17, 2015
RegMed’s close: heightened volatility as sector declines in a game of probabilities
July 14, 2015
Just as I thought I could get a day off, news hits and it usually sticks
35 companies, 1 interpreter!
Insight, foresight and recommendation
Vericel (VCEL) – Opened 1/2/18 at $5.90, saw a high of $7.30; started February at $8.15 slipping with a low of $6.60 and started March at $8.05 jumping to $11.35 on $3/6 after announcing a $300 K net incomeand a per share value of +$0.01. Further thoughts rflect strong use of an ATM and at this "peak" - a financing "could" ensue ...
sellMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.